G1 Therapeutics Starts Mid-Stage Bladder Cancer Trial With Cosela

by Vandana Singh, Benzinga Editor

June 14, 2021 9:33 AM | 1 min read |

G1 Therapeutics Inc GTHX has initiated the PRESERVE 3 Phase 2 study evaluating Cosela (trilaciclib) in patients with untreated, locally advanced, or metastatic urothelial carcinoma (mUC).
Cosela will be administered with first-line platinum-based chemotherapy and the immune checkpoint inhibitor avelumab maintenance therapy. Myeloprotection and anti-tumor efficacy endpoints are being assessed in this study. The initial results of this study are expected in the second half of 2022.
Patient recruitment in Preserve 3 is now underway. The study will enroll approximately 90 patients.
Price Action: GTHX shares are up 1.06% at $21.85 during the market session on the last check Monday.